PTC Therapeutics Provides Update on CHMP Opinion for Conditional...

The response from the CHMP is consistent with the Company's previous guidance concerning the substantial risks regarding conditional EMA approval and underscores the importance of PTC's work in completing the ongoing confirmatory Phase 3 clinical trial.

http://ift.tt/KTUwn9